Scientific Presentations & Publications

Title	Published Date
Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress	Jun 09 2023
Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes	Apr 18 2023
Notable Labs Presents Clinical Platform Validation Data at the 2023 AACR Conference	Apr 18 2023
Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML- Advances in Pediatric Acute Myeloid Leukemia	Jan 18 2023
Successful Treatment with Bortezomib, Panobinostat, and Dexamethasone of Acute Myeloid Leukemia (AML) in 2nd Relapse After Allogeneic Stem Cell Transplantation (SCT): Therapy Selected Based Upon Results of a Personalized Flow Cytometric Screen for Drug	Aug 11 2022
Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib as a Potential Novel Drug Combination for Pediatric AML	Dec 16 2021
Prediction of clinical response to venetoclax plus decitabine in AML using a 7-day ex vivo assay	Dec 16 2021
Ex vivo drug sensitivity assay correlates with clinical response in pediatric AML	Jul 21 2021
Correlation of ex vivo drug sensitivity with clinical response in pediatric AML	Jul 21 2021
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	Mar 12 2021
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms	Oct 09 2020
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric AML Study	Oct 08 2020
PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells	Jul 11 2020
Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples	Jul 02 2020
Early Results from a Biomarker-Directed Phase 2 Trial of SY-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following SY-1425 Treatment	Jul 01 2020
RARA Pathway Activation Biomarkers in Study SY-1425-201 Define a New Subset of AML and MDS Patients and Correlate with Myeloid Differentiation Following Ex Vivo SY 1425 Treatment	Jul 01 2020
Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients	Jul 01 2020
SY-1425, A Potent and Selective RARA Agonist, Reprograms AML Cells for Differentiation Along Distinct Lineages Uncovering PD Markers for Clinical Studies	Jul 01 2020
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options	Jul 01 2020
A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents	Jul 01 2020

Page 1 of 2

To learn more, share ideas, or join our mission.
Contact us today!

CONNECT WITH US